TY - JOUR
T1 - The missing linkage
T2 - What pharmacogenetic associations are left to find in CYP3A?
AU - Perera, Minoli
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Importance of the field: An enormous amount of drugs and endogenous substrates are metabolized by the enzymes encoded in the CYP3A gene cluster, making variation at this locus of utmost importance in the field of pharmacogenetics. However, the identification of genetic variation that contributes to the wide phenotypic variability at this locus has been elusive. While dozens of studies have investigated the effects of coding variants, none have found the definitive answer to what variant or variants explain the distribution of enzyme activity and clinical effects seen with the drug metabolized by these genes. Areas covered in this review: This review highlights the recent pharmacogenetic work at the CYP3A locus, in particular studies on known functional variants in CYP3A4 and CYP3A5. In addition, common pharmacogenetic strategies as well as considerations specific to the CYP3A locus are discussed. What the reader will gain: The reader will gain a greater understanding of the complexities involved in studying the CYP3A locus, population differences that may affect pharmacogenetic studies at this locus and the importance of variation that affect gene regulation. Take home message: More innovative and comprehensive methods to assay this region are needed, with particular attention paid to the role of gene regulation and non-coding sequence.
AB - Importance of the field: An enormous amount of drugs and endogenous substrates are metabolized by the enzymes encoded in the CYP3A gene cluster, making variation at this locus of utmost importance in the field of pharmacogenetics. However, the identification of genetic variation that contributes to the wide phenotypic variability at this locus has been elusive. While dozens of studies have investigated the effects of coding variants, none have found the definitive answer to what variant or variants explain the distribution of enzyme activity and clinical effects seen with the drug metabolized by these genes. Areas covered in this review: This review highlights the recent pharmacogenetic work at the CYP3A locus, in particular studies on known functional variants in CYP3A4 and CYP3A5. In addition, common pharmacogenetic strategies as well as considerations specific to the CYP3A locus are discussed. What the reader will gain: The reader will gain a greater understanding of the complexities involved in studying the CYP3A locus, population differences that may affect pharmacogenetic studies at this locus and the importance of variation that affect gene regulation. Take home message: More innovative and comprehensive methods to assay this region are needed, with particular attention paid to the role of gene regulation and non-coding sequence.
KW - CYP3A
KW - Drug metabolizing enzymes
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=72949092029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72949092029&partnerID=8YFLogxK
U2 - 10.1517/17425250903379546
DO - 10.1517/17425250903379546
M3 - Review article
C2 - 19968573
AN - SCOPUS:72949092029
SN - 1742-5255
VL - 6
SP - 17
EP - 28
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
IS - 1
ER -